KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares Issued
Ratios

Moderna (MRNA) Accumulated Depreciation & Amortization (2016 - 2025)

Historic Accumulated Depreciation & Amortization for Moderna (MRNA) over the last 10 years, with Q3 2025 value amounting to $51.0 million.

  • Moderna's Accumulated Depreciation & Amortization changed 0.0% to $51.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $51.0 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $185.0 million for FY2024, which is 7001.62% down from last year.
  • As of Q3 2025, Moderna's Accumulated Depreciation & Amortization stood at $51.0 million, which was down 0.0% from $56.0 million recorded in Q2 2025.
  • Over the past 5 years, Moderna's Accumulated Depreciation & Amortization peaked at $617.0 million during Q4 2023, and registered a low of $15.0 million during Q1 2021.
  • Moreover, its 5-year median value for Accumulated Depreciation & Amortization was $76.0 million (2022), whereas its average is $131.0 million.
  • As far as peak fluctuations go, Moderna's Accumulated Depreciation & Amortization soared by 77500.0% in 2021, and later crashed by 7926.83% in 2024.
  • Moderna's Accumulated Depreciation & Amortization (Quarter) stood at $232.0 million in 2021, then skyrocketed by 50.0% to $348.0 million in 2022, then surged by 77.3% to $617.0 million in 2023, then tumbled by 70.02% to $185.0 million in 2024, then tumbled by 72.43% to $51.0 million in 2025.
  • Its Accumulated Depreciation & Amortization stands at $51.0 million for Q3 2025, versus $56.0 million for Q2 2025 and $38.0 million for Q1 2025.